Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma
Trial Details
- NCT ID
- NCT06932861
- Phase
- EARLY_PHASE1
- Sponsor
- Xinxin Zhang
- Status
- RECRUITING
- Cancer Type
- Sarcoma
- Interventions
- personalized neoantigen mRNA vaccine
- Locations (sample)
- Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
- Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
- Age ≥ 6 years;
- Has residual tumor or minor disease progression following standard therapy, and has no available effective treatment option. (\*: Prior to vaccine …
- Expected survival time greater than 6 months;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →